全文获取类型
收费全文 | 2900篇 |
免费 | 326篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 123篇 |
妇产科学 | 62篇 |
基础医学 | 339篇 |
口腔科学 | 90篇 |
临床医学 | 277篇 |
内科学 | 519篇 |
皮肤病学 | 24篇 |
神经病学 | 346篇 |
特种医学 | 124篇 |
外科学 | 432篇 |
综合类 | 63篇 |
一般理论 | 3篇 |
预防医学 | 377篇 |
眼科学 | 92篇 |
药学 | 150篇 |
中国医学 | 1篇 |
肿瘤学 | 196篇 |
出版年
2021年 | 35篇 |
2019年 | 44篇 |
2018年 | 43篇 |
2017年 | 53篇 |
2016年 | 39篇 |
2015年 | 50篇 |
2014年 | 66篇 |
2013年 | 93篇 |
2012年 | 139篇 |
2011年 | 145篇 |
2010年 | 82篇 |
2009年 | 108篇 |
2008年 | 136篇 |
2007年 | 180篇 |
2006年 | 169篇 |
2005年 | 161篇 |
2004年 | 162篇 |
2003年 | 140篇 |
2002年 | 123篇 |
2001年 | 75篇 |
2000年 | 46篇 |
1999年 | 64篇 |
1998年 | 50篇 |
1997年 | 42篇 |
1996年 | 38篇 |
1995年 | 34篇 |
1994年 | 34篇 |
1993年 | 27篇 |
1992年 | 30篇 |
1991年 | 36篇 |
1990年 | 36篇 |
1989年 | 44篇 |
1988年 | 41篇 |
1987年 | 53篇 |
1986年 | 37篇 |
1985年 | 35篇 |
1984年 | 39篇 |
1983年 | 29篇 |
1982年 | 40篇 |
1981年 | 38篇 |
1980年 | 29篇 |
1978年 | 22篇 |
1977年 | 27篇 |
1976年 | 23篇 |
1975年 | 20篇 |
1974年 | 34篇 |
1973年 | 30篇 |
1972年 | 26篇 |
1971年 | 21篇 |
1970年 | 20篇 |
排序方式: 共有3237条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
5.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献
6.
7.
8.
9.
10.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献